New England Journal of Medicine Publishes Results of Phase III FLAURA T
Tagrisso demonstrated superior progression-free survival (PFS) of 18.9 month...
2017-11-21
文传商讯
AstraZeneca and Chi-Med’s Savolitinib Shows Encouraging Clinical Activ
Data for savolitinib in combination with Tagrisso or Iressa presented at Wor...
2017-10-17
文传商讯
Boehringer Ingelheim HCP Survey: Nearly 20% of newly diagnosed lung can
International survey showed high global EGFR testing rates prior to first-li...
2016-12-09
文传商讯
New data on olmutinib (BI 1482694) presented at ASCO 2016 underscores c
Promising efficacy and safety profile of olmutinib* (BI 1482694) is reaffirm...
2016-06-07
文传商讯
Boehringer Ingelheim launches ambitious ELUXA trial programme to broadl
Comprehensive ELUXA trial programme explores olmutinib* (BI 1482694) as a mo...
2016-06-04
文传商讯
South Korea is first to approve next generation lung cancer treatment o
Olmutinib* (BI 1482694 / HM61713) is first TKI therapy approved in South Kor...
2016-05-21
文传商讯
阿斯利康在ELCC 2016上呈报Tagrisso (osimertinib)治疗肺癌的阳性随访数据
I期数据显示，Tagrisso一线治疗EGFRm NSCLC患者的客观缓解率达77%，无进展生存期达...
2016-04-19
文传商讯
Head-to-head study demonstrating Giotrif (afatinib) significantly impro
LUX-Lung 7 trial showed afatinib significantly reduced the risk of lung canc...
2016-04-14
文传商讯
